NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT
“In the matter of Regeneron Pharmaceuticals, Inc. v Mylan Pharmaceuticals Inc. and Biocon Biologics Inc. (Case No. 22-061), the U.S. District Court for the Northern District of West Virginia issued a mixed decision pertaining to three of Regeneron’s patents purporting to cover certain formulations and methods of treatment relating to the ophthalmic product, EYLEA® (aflibercept) Injection. The court decided that certain claims of the method of treatment patents (U.S. Patent Nos. 10,888,601 and 11,253,572) were invalid, while certain claims of the formulation patent (U.S. Patent No. 11,084,865) were held valid and infringed.
Biocon Biologics is an innovation-driven company and will continue to aggressively pursue its mission of bringing high-quality affordable biosimilars to patients in the United States.” – Company Spokesperson
For more information email: seema.ahuja@biocon.com
